BioCentury | Jul 27, 2020
Deals

AZ goes early for its latest $1B ADC deal with Daiichi

With the success of Enhertu as the template, AstraZeneca is putting at least a further $1 billion on the line for a much earlier stage ADC in a new deal with Daiichi Sankyo. AstraZeneca plc...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
BioCentury | Feb 11, 2019
Preclinical News

Scripps miRNA flips HER2-negative tumors to HER2-positive

...factor receptor 2; S1P - Sphingosine 1-phosphate; SPHK1 - Sphingosine kinase 1 Mark Zipkin [vic-]trastuzumab duocarmazine, Anti-HER2-ADC (SYD985) Herceptin...
BioCentury | Oct 12, 2015
Clinical News

Anti-HER2-ADC: Interim Phase I data

...Phase I SYD985.001 trial showed that 0.3, 0.6, 1.2 and 2.4 mg/kg doses of IV SYD985...
...reported. The MTD was not reached. In 9 evaluable patients who received >=2 cycles of SYD985...
...the European Cancer Congress in Vienna. Synthon B.V. , Nijmegen, the Netherlands Product: Anti-HER2-ADC ( SYD985...
BioCentury | Dec 15, 2014
Clinical News

Anti-HER2-ADC: Phase I started

...Synthon began a 2-part, open-label, international Phase I trial of IV SYD985 every 3 weeks in...
...about 76 patients with locally advanced or metastatic solid tumors. The dose-escalation part will test SYD985...
...with HER2-positive breast or gastric cancer. Synthon B.V. , Nijmegen, the Netherlands Product: Anti-HER2-ADC ( SYD985...
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Cancer

...work includes testing the lead compound in rodent xenograft models for undisclosed cancers. Synthon B.V.'s anti-HER2-ADC...
BioCentury | Feb 11, 2013
Clinical News

Synthon preclinical data

...HER2 ; ErbB2 ; neu)-positive breast cancer and non-small cell lung cancer (NSCLC), Synthon's anti-HER2-ADC...
...and its Genentech Inc. unit market Herceptin trastuzumab. Synthon B.V. , Nijmegen, the Netherlands Product: Anti-HER2-ADC...
Items per page:
1 - 7 of 7